Abstracts tagged "Abatacept and macrophages"

Abstract Number: 2164 • 2012 ACR/ARHP Annual Meeting
Evidence for NF-Kb Intracellular Signaling Involvement Following CTLA4-Ig (Abatacept) Treatment of Human Macrophages
Renata Brizzolara¹, Paola Montagna¹, Stefano Soldano², Alberto Sulli³, Bruno Seriolo⁴, Barbara Villaggio⁵, Pierfranco Triolo⁶, Lamberto Felli⁷ and Maurizio Cutolo⁸, ¹Department of Internal Medicine, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ³Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁵Research Laboratory of Nephrology, Department of Internal Medicine, University of Genova, Genova, Italy, ⁶Rheumatoid Arthritis Unit, Orthopedic Surgery Department, CTO Hospital, Turin, taly, Turin, Italy, ⁷Orthopedic Department, University of Genova, Genova, Italy, ⁸Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy
Background/Purpose: The transcription factor NF-kB is an intracellular signaling essential for the expression of a variety of immune-response genes, including those related to pro-inflammatory cytokines…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].